TEL-AVIV, Israel, November 8, 2017
Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed the first of a cluster of patent applications with the US Patent & Trademark Office (USPTO) which covers their ongoing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body.
The pioneering work based on profiling and modulating patient-derived microbiota, personalizes and profiles individual health status. This will make possible the optimization of pharmacological treatments for patients.
Dr. Moran Grinberg, VP of R&D of Cannabics Pharmaceuticals said “Our new integrated approach will allow patients and practitioners to receive a more accurate, personalized result pertaining to their particular individual status. Today we are at the midst of a technological revolution that combines algorithms predicting medical treatment that is based on cumulative clinical data. Therefore, we believe that the integration of multi-system data derived from our screening technologies will provide a comprehensive overview on the patient`s condition”.
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 17th, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.